Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYC | P01106 | 2/20 | 0.41 |
| ▸ | MAX | P61244 | 2/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.40 |
| ▸ | RXRA | P19793 | 1/20 | 0.39 |
| ▸ | RXRB | P28702 | 1/20 | 0.39 |
| ▸ | RXRG | P48443 | 1/20 | 0.39 |
| ▸ | XDH | P47989 | 1/20 | 0.39 |
| ▸ | EP300 | Q09472 | 3/20 | 0.38 |
| ▸ | GCK | P35557 | 5/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2653455 | 0.87 | AR (0.41) | MYCMAXXDHGCKPDE4B | |
| SCHEMBL2653534 | 0.82 | GCK (0.58) | GCKKCNH2 | |
| SCHEMBL19438617 | 0.80 | CA12 (0.51) | GCKPOLBHSD17B10TDP1L3MBTL1 | |
| SCHEMBL2653773 | 0.79 | GCK (0.43) | MYCMAXGCKKCNH2 | |
| SCHEMBL9903306 | 0.77 | KDM4E (0.49) | GCKHSD17B10TDP1 | |
| SCHEMBL5218574 | 0.76 | PTGER1 (0.44) | GCKPOLBHSD17B10TDP1L3MBTL1 | |
| SCHEMBL2655556 | 0.74 | GCK (0.52) | GCKKCNH2 | |
| SCHEMBL2654689 | 0.74 | KDM5A (0.43) | GCKPTGER1 | |
| SCHEMBL18585733 | 0.71 | KDM4E (0.45) | MYCXDHPOLBHSD17B10TDP1 | |
| SCHEMBL9903857 | 0.71 | GCK (0.37) | GCKKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709505-B2 | Benzofuran derivatives, process for their preparation and intermediates thereof | ASTRAZENECA AB (SE) | 2010-05-04 | — | — | US | disclosed |
| EP-1578745-B1 | BENZOFURAN DERIVATivES, PROCESS FOR THEIR PREPARATION AND INTERMEDIATES THEREOF | ASTRAZENECA AB (SE) | 2007-11-14 | — | — | EP | disclosed |
| US-20060058353-A1 | Benzofuran derivatives, process for their preparation and intermediates thereof | ASTRAZENECA AB (SE) | 2006-03-16 | — | — | US | disclosed |
| EP-1578745-A1 | BENZOFURAN DERIVATES, PROCESS FOR THEIR PREPARATION AND INTERMEDIATES THEREOF | Astrazeneca AB (SE) | 2005-09-28 | — | — | EP | disclosed |
| WO-2004046139-A1 | BENZOFURAN DERIVATES, PROCESS FOR THEIR PREPARATION AND INTERMEDIATES THEREOF | ASTRAZENECA AB (SE) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058353-A1 | Benzofuran derivatives, process for their preparation and intermediates thereof | GCK, PDK2, GCKR | MYC 1953/4885MAX 2420/4885NR1H4 4587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.